Literature DB >> 3309192

Subacute leucoencephalopathy induced by carmofur, a 5-fluorouracil derivative.

S Kuzuhara1, N Ohkoshi, K Kanemaru, H Hashimoto, T Nakanishi, Y Toyokura.   

Abstract

Three cases of leucoencephalopathy induced by carmofur (1-hexylcarbamoyl-5-fluorouracil), an antineoplastic derivative of 5-fluorouracil are reported and the literature is reviewed. Initial symptoms were unsteady gait and dementia developing several weeks or months after carmofur had been started. Symptoms increased gradually even after stopping the drug. Severe encephalopathy with confusion, delirium or coma appeared frequently. Symptoms were usually reversible but death occasionally occurred. The EEG showed marked slowing. Computed tomography of the brains of severely intoxicated patients showed marked hypodensity of the entire cerebral white matter. Carmofur must be discontinued immediately if any psychomotor symptoms develop.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3309192     DOI: 10.1007/BF00314079

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  12 in total

1.  ACUTE CEREBELLAR SYNDROME SECONDARY TO 5-FLUOROURACIL THERAPY.

Authors:  J L RIEHL; W J BROWN
Journal:  Neurology       Date:  1964-10       Impact factor: 9.910

2.  Letter: Organic mental changes with fluorouracil therapy.

Authors:  E S Greenwald
Journal:  JAMA       Date:  1976-01-19       Impact factor: 56.272

Review 3.  Neurotoxicity of commonly used antineoplastic agents (first of two parts).

Authors:  H D Weiss; M D Walker; P H Wiernik
Journal:  N Engl J Med       Date:  1974-07-11       Impact factor: 91.245

4.  Antitumor activity of 1-hexylcarbamoyl-5-fluorouracil in a variety of experimental tumors.

Authors:  A Hoshi; M Iigo; A Nakamura; M Yoshida; K Kuretani
Journal:  Gan       Date:  1976-10

5.  Neuropathologic study on chronic neurotoxicity of 5-fluorouracil and its masked compounds in dogs.

Authors:  R Okeda; T Karakama; S Kimura; S Toizumi; T Mitsushima; Y Yokoyama
Journal:  Acta Neuropathol       Date:  1984       Impact factor: 17.088

6.  Metabolic fate of 1-hexylcarbamoyl-5-fluorouracil in rats.

Authors:  T Kobari; K Tan; M Kumakura; S Watanabe; I Shirakawa; H Kobayashi; A Ujiie; Y Miyama; H Namekawa; H Yamamoto
Journal:  Xenobiotica       Date:  1978-09       Impact factor: 1.908

7.  [Clinical evaluation of 1-hexylcarbamoyl-5-fluorouracil (HCFU) in hepatocellular carcinoma].

Authors:  K Shiraishi; Y Kubo; Y Majima; K Sato; T Sakemi; T Sakai; K Hirai; F Ninomiya; M Abe; K Tanikawa
Journal:  Gan To Kagaku Ryoho       Date:  1984-11

8.  Antitumor activity of 1-alkylcarbamoyl derivatives of 5-fluorouracil in a variety of mouse tumors.

Authors:  M Iigo; A Hoshi; A Nakamura; K Kuretani
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

9.  "Organic brain syndrome" secondary to 5-fluorouracil toxicity.

Authors:  H T Lynch; C P Droszcz; W A Albano; J F Lynch
Journal:  Dis Colon Rectum       Date:  1981 Mar-Apr       Impact factor: 4.585

10.  Computer assisted tomography in methotrexate encephalopathy.

Authors:  N Peylan-Ramu; D G Poplack; C L Blei; J R Herdt; M Vermess; G Di Chiro
Journal:  J Comput Assist Tomogr       Date:  1977-04       Impact factor: 1.826

View more
  4 in total

1.  Carmofur-induced leukoencephalopathy: MRI.

Authors:  S Matsumoto; S Nishizawa; M Murakami; S Noma; A Sano; Y Kuroda
Journal:  Neuroradiology       Date:  1995-11       Impact factor: 2.804

2.  Experimental neurotoxicity of 5-fluorouracil and its derivatives is due to poisoning by the monofluorinated organic metabolites, monofluoroacetic acid and alpha-fluoro-beta-alanine.

Authors:  R Okeda; M Shibutani; T Matsuo; T Kuroiwa; R Shimokawa; T Tajima
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

Review 3.  Role of inflammation and oxidative stress in chemotherapy-induced neurotoxicity.

Authors:  Pooja Gupta; Tavneet Kaur Makkar; Lavisha Goel; Monika Pahuja
Journal:  Immunol Res       Date:  2022-07-20       Impact factor: 4.505

4.  Genetic ablation of acid ceramidase in Krabbe disease confirms the psychosine hypothesis and identifies a new therapeutic target.

Authors:  Yedda Li; Yue Xu; Bruno A Benitez; Murtaza S Nagree; Joshua T Dearborn; Xuntian Jiang; Miguel A Guzman; Josh C Woloszynek; Alex Giaramita; Bryan K Yip; Joseph Elsbernd; Michael C Babcock; Melanie Lo; Stephen C Fowler; David F Wozniak; Carole A Vogler; Jeffrey A Medin; Brett E Crawford; Mark S Sands
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-16       Impact factor: 11.205

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.